{
  "id": 20550386,
  "title": "PolyNovo at Bell Potter Healthcare Conference: growth broadens beyond burns",
  "url": "https://urgent.news/2026/11/18/polynovo-at-bell-potter-healthcare-conference-growth-broadens-beyond",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T05:34:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/polynovo-at-bell-potter-healthcare-conference-growth-broadens-beyond-burns-93CH-5034753"
  },
  "original_language": "en",
  "account": "PolyNovo, the burns-focused healthcare company, showcased its expanding business at the Bell Potter Healthcare Conference. The company reported a 16.7 percent rise in FY2026 product sales to AUD 138.4 million, alongside a 50 percent increase in underlying EBITDA to AUD 13.4 million. Growth outside burns, particularly in the U.S., was noteworthy, with non-burn sales climbing 52.8 percent over the past three years. PolyNovo's NovoSorb platform, now treating over 130,000 patients in 50 countries, is gaining traction in complex wound care. The company plans to launch NovoSorb SynPath in the outpatient market and has nearly 300 U.S. accounts using MTX, with many increasing BTM usage. Management anticipates a U.S. premarket approval filing for full-thickness burns and aims to launch NovoSorb SynPath in the outpatient market. The company's success is attributed to diversification beyond burns, with operations expanding to include trauma, surgical reconstruction, and limb salvage. PolyNovo estimates this broader patient population is three to four times larger than burns alone.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}